Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A

This article was originally published in The Pink Sheet Daily

Executive Summary

A chance discovery at a U.K. hospital led to the synthesis of an antibody that could prevent blood clots without causing excessive bleeding. Index Ventures created and funded single-asset company XO1 to conduct first-in-man tests on the compound by 2015.

You may also be interested in...



Medicxi Ventures Launches With €210 Million Fund

Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its "asset-centric" approach to investing.

Deal Watch: Valeant Increases Bid, Wrests Salix Away From Endo

Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.

Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings

More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel